Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial.
dc.contributor.author | Middleton, G | |
dc.contributor.author | Silcocks, P | |
dc.contributor.author | Cox, T | |
dc.contributor.author | Valle, Juan W | |
dc.contributor.author | Wadsley, J | |
dc.contributor.author | Propper, D | |
dc.contributor.author | Coxon, F | |
dc.contributor.author | Ross, P | |
dc.contributor.author | Madhusudan, S | |
dc.contributor.author | Roques, T | |
dc.contributor.author | Cunningham, D | |
dc.contributor.author | Falk, S | |
dc.contributor.author | Wadd, N | |
dc.contributor.author | Harrison, M | |
dc.contributor.author | Corrie, Pippa | |
dc.contributor.author | Iveson, Tim | |
dc.contributor.author | Robinson, A | |
dc.contributor.author | McAdam, K | |
dc.contributor.author | Eatock, M | |
dc.contributor.author | Evans, J | |
dc.contributor.author | Archer, C | |
dc.contributor.author | Hickish, T | |
dc.contributor.author | Garcia-Alonso, A | |
dc.contributor.author | Nicolson, M | |
dc.contributor.author | Steward, W | |
dc.contributor.author | Anthoney, A | |
dc.contributor.author | Greenhalf, W | |
dc.contributor.author | Shaw, V | |
dc.contributor.author | Costello, E | |
dc.contributor.author | Naisbitt, D | |
dc.contributor.author | Rawcliffe, C | |
dc.contributor.author | Nanson, G | |
dc.contributor.author | Neoptolemos, J | |
dc.date.accessioned | 2014-07-08T14:15:11Z | |
dc.date.available | 2014-07-08T14:15:11Z | |
dc.date.issued | 2014-07 | |
dc.identifier.citation | Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial. 2014, 15 (8):829-40 Lancet Oncol | en |
dc.identifier.issn | 1474-5488 | |
dc.identifier.pmid | 24954781 | |
dc.identifier.doi | 10.1016/S1470-2045(14)70236-0 | |
dc.identifier.uri | http://hdl.handle.net/10541/322604 | |
dc.description.abstract | We aimed to assess the efficacy and safety of sequential or simultaneous telomerase vaccination (GV1001) in combination with chemotherapy in patients with locally advanced or metastatic pancreatic cancer. | |
dc.language.iso | en | en |
dc.rights | Archived with thanks to The lancet oncology | en |
dc.title | Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial. | en |
dc.type | Article | en |
dc.contributor.department | University of Birmingham, Edgbaston, Birmingham, UK. | en |
dc.identifier.journal | The Lancet Oncology | en |
refterms.dateFOA | 2020-05-01T15:07:50Z | |
html.description.abstract | We aimed to assess the efficacy and safety of sequential or simultaneous telomerase vaccination (GV1001) in combination with chemotherapy in patients with locally advanced or metastatic pancreatic cancer. |